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Objective:Neovascularization is a physiologic repair process that partly depends on nitric oxide. Extracellular superoxide
dismutase (EcSOD) is the major scavenger of superoxide. It is an important regulator of nitric oxide bioavailability and
thus protects against vascular dysfunction. We hypothesized that overexpression of EcSOD in skeletal muscle would
improve recovery from hind-limb ischemia.
Methods: Adeno-associated virus serotype 9 (AAV9) vectors expressing EcSOD or luciferase (control) from the cytomeg-
alovirus promoter were cross-packaged into AAV9 capsids and injected intramuscularly into the hind-limb muscles (1 
1011 viral genomes/limb) of 12-week-old mice. Ischemia was induced after intramuscular injections. Laser Doppler was used
tomeasure limbperfusion ondays 0, 7, and 14 after injection.Valueswere expressed as a ratio relative to the nonischemic limb.
EcSOD expression was measured by Western blotting. Capillary density was documented by immunohistochemical staining
for platelet endothelial cell adhesion molecule. Apoptosis was assessed by terminal deoxynucleotide transferase-mediated
biotin-deoxy uridine triphosphate nick-end labeling and necrosis was visually evaluated daily.
Results: EcSOD expression was twofold upregulated in EcSOD treated vs control ischemic muscles at day 14. Capillary
density (capillaries/fiber) was 1.9-fold higher in treated (1.65  0.02) vs control muscle (0.78  0.17, P < .05).
Recovery of perfusion ratio at day 14 after ischemia was 1.5-fold greater in EcSOD vs control mice (P < .05). The
percentage of apoptotic nuclei was 1.3%  0.4% in EcSOD-treated mice compared with 4.2%  0.2% in controls (P <
.001). Limb necrosis was also significantly lower in EcSOD vs control mice.
Conclusion: AAV9-mediated overexpression of EcSOD in skeletal muscle significantly improves recovery from hind-limb ischemia
in mice, consistent with improved capillary density and perfusion ratios in treated mice. (J Vasc Surg 2011;54:810-8.)
Clinical Relevance: Atherosclerosis remains a major cause of morbidity and mortality in the Western world. Extensive
research has been conducted to attempt to harness the ability to facilitate the growth of blood vessels to limit the
complications that follow an arterial occlusion. In no area of medicine is this needed greater than in peripheral arterial
disease (PAD), where patients continue to experience high rates of poor wound healing and amputation. Gene therapy has
been attempted in humans, with mixed results to date. Our study used a preclinical model of surgically induced hind-limb
ischemia in a strain of mice that have a low rate of endogenous perfusion recovery from ischemia and a high risk of
necrosis. We used an adeno-associated virus serotype 9 (AAV9) as the vector to deliver the gene expressing extracellular
superoxide dismutase (EcSOD). Intramuscular EcSOD demonstrated a beneficial effect in this preclinical model. The
AAV9 was able to induce high levels of gene expression without inducing detectable inflammation. This study may serve
as a foundation for the future investigation of EcSOD, AAV9, or both, in PAD.
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iPeripheral arterial disease (PAD) is a major health
care problem in the United States, with an age-adjusted
prevalence of 12% that is expected to increase because of
the aging population.1,2 Intermittent claudication and
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810ritical limb ischemia are the two major clinical manifes-
ations of PAD. Medical treatments for patients with
AD include antiplatelet agents, angiotensin-converting
nzyme inhibitors, and cholesterol-lowering medica-
ions (statins); however, these treatments have no signif-
cant effect on limb outcomes, such as the risk for major
mputation.1,2
Angiogenesis is the growth and development of new
apillaries from pre-existing vasculature, and therapeutic
ngiogenesis seeks to harness this phenomenon to improve
lood flow and treat disorders of inadequate tissue perfu-
ion.3 The administration of cytokine growth factors to
romote therapeutic angiogenesis has been met with lim-
ted clinical success.4 Bone marrow-derived stem cells and
rogenitor cells are potential new therapeutic options to
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Volume 54, Number 3 Saqib et al 811improve leg perfusion or wound healing, or both, that have
shown promising results, and several large randomized,
placebo-controlled, double-blind studies are currently on-
going.5,6
Neovascularization can be an adaptive mechanism that
preserves tissue integrity despite vascular occlusions and the
resulting ischemic injury. Extracellular superoxide dismu-
tase (EcSOD) serves as a scavenger of superoxide, which
increases nitric oxide (NO) bioavailability in the blood
vessel wall7 by protecting it against superoxide-mediated
conversion to peroxynitrite. In vessels with high levels of
superoxide, NO is converted to peroxynitrite and may fail
to reach smooth muscle cells, thereby producing endothe-
lial dysfunction. EcSOD, which constitutes a large portion
of total SOD in the vessel wall, is strategically located to
protect NO during its diffusion to smooth muscle.7,8
Kim et al9 showed that impaired neovascularization in
EcSOD–/– mice is associated with enhanced superoxide
production, apoptotic cells positive by terminal deoxy-
nucleotidyl transferase nick-end labeling (TUNEL), and
decreased levels of NO2–/NO3– and cyclic guanosine
monophosphate (cGMP) in ischemic tissues compared
with wild-type mice.
The fundamental biologic properties of EcSOD and
our recent findings from adeno-associated virus serotype 9
(AAV9)–mediated overexpression of EcSOD in the heart10
led us to hypothesize that overexpression of EcSOD in
skeletal muscle would similarly increase capillary density
and thereby improve recovery from hind-limb ischemia in
BALB/cmice, a strain that has poor perfusion recovery and
is prone to develop necrosis of the affected limb.11
Recombinant viral vectors based on the nonpathogenic
human parvovirus, AAV, have a number of attractive fea-
tures, including lack of cytotoxicity, ability to transduce
dividing and nondividing cells, and long-term transgene
expression.12 AAV9, which is under development for gene
therapy applications, shows significantly enhanced trans-
duction efficiency inmuscle.13We therefore selected AAV9
as a vector for delivering the gene that expresses EcSOD to
ischemic skeletal muscles in the murine model of hind-limb
ischemia.
MATERIALS AND METHODS
Mice and experimental protocol. All protocols and
procedures conformed to the Guidelines for Use of Labora-
tory Animals published by theUnited States Department of
Health and Human Services and were approved by the
University of Virginia Animal Care andUse Committee. All
animals received care in accordance with Principles of Lab-
oratory Animal Care, formulated by the National Society
for Medical Research, and Guide for the Care and Use of
Laboratory Animals (National Institutes of Health publica-
tion No. 86-23, revised 1985). All age-matched (12- to
16-week-old) male mice were obtained from the Jackson
Laboratory (Bar Harbor, Me).
Plasmids. The AAV vectors used in this study were
derived from plasmid pACS, as described previously.14 To
create an AAV vector-generating plasmid in which the sytomegalovirus (CMV) immediately early promoter drives
he expression of the firefly luciferase gene pACMVLuc, a
.2-kb HindIII-BamHI fragment carrying the firefly lu-
iferase complementary DNA (cDNA) was excised from
lasmid pGL3 (Promega Corp, Madison, Wisc) and in-
erted between the HindIII and BamHI sites of pACS.
lasmid pACMVEcSOD, an AAV-generating plasmid har-
oring mouse EcSOD driven by the CMV promoter was
onstructed by inserting a mouse EcSOD cDNA between
he NheI and BamHI sites of pACS.
AAV vector production and purification. AAV vec-
ors were packaged into AAV9 capsids by the triple trans-
ection method in human embryonic kidney (HEK) 293
ells. Helper plasmids pAdF6 (providing the three adeno-
iral helper genes) and plasmid p5E18-VD2/9 (providing
AV2 rep and AAV9 capsid genes) were provided by Dr
ames M. Wilson.15,16 The AAV-generating plasmid and
elper plasmids were transfected into HEK 293 cells by the
alcium-phosphate coprecipitation method. A total of 50
g of plasmid DNA (mixed in equimolar ratio) was used
er 15-cm cell culture plate. AAV vectors were purified 3
ays after transfection by ammonium sulfate fractionation
nd iodixanol gradient centrifugation.17 Virus particles
ere resuspended in 1 mL of Dulbecco’s phosphate buff-
red saline containing 1 mM MgCl2 and 2.5 mM KCl
DPBS-MK), dialyzed against DPBS-MK, and stored at
80°C.
Determination of AAV vector titer. Titers for the
AV vectors (viral genomes [vg]/mL) were determined by
uantitative real-time polymerase chain reaction as de-
cribed previously.18 The primers used for amplifying lu-
iferase were:
5=-AGAACTGCCTGCGTGAGATT-3= (forward) and
5=-AAAACCGTGATGGAATGGAA-3= (reverse)
EcSOD was similarly amplified using:
5=CCTAGCAGACAGGCTTGACC-3= (forward), and
5=-CCATCCAGATCTCCAGCACT-3= (reverse).
Known copy numbers (105–108) of the respective plas-
ids (pACMVLuc, or pACMVEcSOD) carrying the appro-
riate cDNAs were used to construct standard curves.
Bioluminescence imaging. Bioluminescence imaging
as performed using C57BL/6mice (n 6). Animals were
nesthetized and maintained on 1% to 1.2% isoflurane in
xygen. D-luciferin (0.15 mg/g; Xenogen Corp, Alameda,
alif) was administered to mice by intraperitoneal injec-
ion. All mice were imaged 8 minutes after D-luciferin
dministration using an in vivo imaging system (IVIS 100;
enogen). Photons emitted from the mice were integrated
or 1 minute. Three serial recordings were done for each
ouse. Images were processed using Living Image soft-
are (Xenogen), as described previously.18
In vitro luciferase assay. Skeletal muscles, livers,
earts, lungs, kidneys, and spleens from the mice injected
ith AAV/CMV/Luc were collected after biolumines-
ence imaging at 28 days after injection. In vitro luciferase
ssays were performed as described previously18 using a
tandardized luciferase assay (Promega Corp).
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September 2011812 Saqib et alInduction of hind-limb ischemia. Mice were anes-
thetized using 2.5% isoflurane for induction and the main-
tenance dose during the surgical procedure was 1.5% iso-
flurane in oxygen. Unilateral femoral artery ligation and
excision, resulting in hind-limb ischemia, was performed as
described previously.19,20 Immediately after surgery, ani-
mals were given a subcutaneous injection of buprenorphine
(0.05 mg/kg). The mice received buprenorphine twice a
day for 48 hours and were closely monitored for any signs
of distress. Postoperative mice were also given acetamino-shen (2 mg/mL), trimethoprim (16 mg/mL), and sulfa-
ethoxazole (80 mg/mL) in their drinking water.
Perfusion recovery and necrosis scores. Blood flow
n the ischemic and contralateral nonischemic limbs was
easured, as described previously, with a laser Doppler
erfusion imaging system (Perimed, Stockholm, Swe-
en).19 Bilateral hind-limb perfusion measures were per-
ormed after light anesthesia with intraperitoneal injections
f a ketamine/xylazine mixture (7 mL saline  2 mL
etamine [100 mg/mL]  1 mL xylazine [20 mg/mL]:
.1-0.15 mL/25 g mouse). Perfusion was expressed as the
atio of the left (ischemic)/right (nonischemic) hind limbs.
Necrosis was visually assessed every day for 7 days after
urgery. The extent of necrosis was scored as grade I,
nvolving only toes; grade II, extending to the dorsum
edis; grade III, extending to the crus (lower leg, extending
rom the ankle to knee); and grade IV, extending to the
high or complete necrosis.21 Mice in which necrosis had
pread to the plantar surface of the foot or that had grade
II necrosis were euthanized in a CO2 chamber.
Gene transfer. Gene transfer was accomplished just
efore the induction of hind-limb ischemia by two 10-
econd intramuscular injections (0.04 mL total) to the
ibialis anterior (TA) and gastrocnemius muscles. A single
perator performed all of the injections.
Tissue procurement, histologic sections, and West-
rn blotting. After the final perfusion measures were per-
ormed, an overdose of anesthetic was given, and the isch-
mic and contralateral TA and gastrocnemius muscles were
urgically excised from tendon to tendon. Euthanasia was
onfirmed using a CO2 chamber. The middle portions of
he muscle were placed in optimal cutting temperature
edium, snap-frozen in liquid nitrogen, mounted, and
ryostat sections (5 m) were prepared. The remainder was
nap-frozen in liquid nitrogen.
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ig. 1. Bioluminescence imaging is shown of vector-injected
ice. A, Mice were injected with adeno-associated virus (AAV)/
ytomegalovirus (CMV)/luciferase (Luc) in the tibialis anterior
nd gastrocnemius muscles (5  1010 viral genomes/muscle).
uciferase expression in these mice was monitored for up to 6
eeks by in vivo bioluminescence imaging using an in vivo imaging
ystem (IVIS; see Materials and Methods). B, Graph shows the
ime course of in vivo AAV serotype 9 (AAV9)–mediated luciferase
xpression in mice injected with AAV9/CMV/Luc in tibialis
nterior and gastrocnemius muscles. The mean values of biolumi-
escence as average radiance (photons/s-cm2-sr) were obtained
rom the regions of interest and plotted against time. C, In vitro
uciferase assays were performed on protein extracts from skeletal
uscles, liver, heart, lungs, and spleen at 6 weeks after the indi-
ated vector injection. Luciferase activity was expressed as relative
ight units (RLU) per milligram of protein and was plotted on a log
cale. The error bars show the standard error of the mean. D,
ild-type mice received a single intramuscular injection of AAV/
MV/Luc or AAV/CMV/-galactosidase (-gal; 1  1011 viral
enomes) in tibialis anterior muscles. -gal staining after 7 days
hows efficient transduction of skeletal muscle fibers. Error bars
how the standard deviation.
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Volume 54, Number 3 Saqib et al 813Protein lysates were prepared, and protein concen-
trations were determined. The muscle homogenates
were separated on polyacrylamide gels, transferred to
polyvinylidene fluoride membranes, blocked, and blot-
ted with antibodies against EcSOD and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). EcSOD protein
expression was determined in nonischemic C57BL/6 and
BALB/c mice as well as in ischemic BALB/c hind limbs.
EcSOD expression was normalized against GAPDH ex-
pression for quantitative analysis.
Capillary density, apoptosis, inflammatory infil-
trate, and cGMP in skeletal muscle. Vascular density in
skeletal muscles was analyzed by immunofluorescent label-
ing using a rat antimouse CD31 antibody (BD Pharmigen,
San Diego, Calif) and visualized using goat antirat conju-
gated with Alexa Fluor 488 (Molecular Probes, Carlsbad,
Calif). Fibers were identified using phalloidin toxin conju-
gated with Alexa Fluor-555 (Molecular Probes). Capillary
density was expressed as capillaries/fiber in eight random
fields (original magnification 200).
Apoptotic cells were stained using ApopTag, an in situ
terminal deoxynucleotide transferase-mediated biotin-
deoxy uridine triphosphate nick-end labeling (TUNEL)
apoptosis kit (Millipore, Temecula, Calif) and quantified as
described previously.21 -Gal histochemistry was per-
Fig 2. Quantitation of adeno-associated virus (AAV) serotype 9
(AAV9)–mediated extracellular superoxide dismutase (EcSOD) ex-
pression is shown in normal hind limb muscles. A, Mice were
injected intramuscularly with AAV/cytomegalovirus (CMV)/lu-
ciferase (Luc) or AAV/CMV/EcSOD (1  1011 viral genomes/
mouse) into the tibialis anterior and gastrocnemius muscles. At
14 days after vector administration, EcSOD expression was
detected by Western blot analysis. Levels of EcSOD expression
were normalized to glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH). B, Expression of EcSOD expression by West-
ern blot analysis was 7.9-fold higher in the EcSOD-treated
group than in controls. *P	 .002. Error bars show the standard
error of the mean.formed as described previously.18 Immunohistochemistry sas performed on frozen sections using polyclonal rabbit
nti-EcSOD antibody (Sigma-Aldrich, St. Louis, Mo), and
at monoclonals CD45 (BD Biosciences) and CD68 (AbD
erotec). For light microscopy, antibodies were detected
sing the avidin-biotin-peroxidase complex (ABC)method
Vector Laboratories, Burlingame, Calif) and visualized
sing 3,3=-diaminobenzidine (DAKO Corp, Carpinteria,
alif). Sections were counterstained with Harris hematox-
lin (Richard-Allen Scientific, Kalamazoo, Mich).
For immunofluorescence microscopy, visualization was
erformed using a goat antirabbit conjugated with Alexa
luor-555 (Molecular Probes), and nuclei were stained
ith 4’,6-diamidino-2-phenylindole (Molecular Probes).
ections were analyzed by light and fluorescence micros-
opy using an Olympus BX51 microscope (Olympus, To-
yo, Japan) and Image Pro Plus 3.0 software (Media Cy-
ernetics, Silver Spring, Md). Infiltration of CD45 and
D68-positive cells was graded as 3 to 5 cells: normal
nfiltrate (score: 0); 6 to 8 cells: mild (score: 1); 9 to 10
ells: moderate (score: 2); 10 cells: severe (score: 3).
issue cGMP levels were determined using an enzyme
mmunoassay system (R&D Systems, Minneapolis, Minn).
Statistical analysis. Data were expressed as means 
ig 3. Quantitation of adeno-associated virus (AAV) serotype
–mediated extracellular superoxide dismutase (EcSOD) expres-
ion in ischemic hind-limb muscles: A, Mice were injected intra-
uscularly with AAV/cytomegalovirus (CMV)/luciferase (Luc)
r AAV/CMV/EcSOD (1 1011 viral genomes/mouse) into the
ibialis anterior and gastrocnemius muscles at the time of hind-
imb ischemia surgery. At 14 days after vector administration
cSOD expression was detected byWestern blot analysis. Levels of
cSOD expression were normalized to glyceraldehyde-3-
hosphate dehydrogenase (GAPDH) protein. B, EcSOD expres-
ion by Western blot analysis was twofold higher in the EcSOD-
reated ischemicmuscles than in controls (n 10 per group). *P	
05). Error bars show the standard error of the mean.tandard error of the mean. The Student t test was used for
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September 2011814 Saqib et alstatistical comparisons of perfusion, capillary density, ap-
optosis, cGMP, and EcSOD expression between two
groups of mice. Comparison of perfusion within each
group at different times was analyzed by repeated-measures
analysis of variance. The significance of the necrosis scores
was assessed using the nonparametric Mann-Whitney U
test. In all cases, P 	 .05 was considered statistically signif-
icant.
RESULTS
Time course of AAV9-mediated luciferase expres-
sion in murine hind-limb nonischemic skeletal muscles.
First, we sought to determine the kinetics of AAV9-
mediated gene expression in normal skeletal muscles. An
AAV9 vector expressing the firefly luciferase gene under the
control of cytomegalovirus promoter (AAV/CMV/Luc)
was injected into right hind-limb (TA and gastrocnemius)
muscles of C57BL/6mice (n 6/group). Seven days after
vector injection, D-luciferin–dependent bioluminescence
was detected in the right TA and gastrocnemius but not in
the left hind limbs (Fig 1, A). The luciferase activity pla-
teaued by 14 days after injection (Fig 1, B). After 28 days,
luciferase activity was 272-fold higher in the right TA and
257-fold higher in the right gastrocnemius compared with
the left TA and gastrocnemius, respectively (Fig 1, C).
Luciferase activities were at background levels in liver,
heart, lungs, kidneys, and spleen.
In a separate experiment,mice (n4/group)were injected
with AAV/CMV/Luc or AAV/CMV/-galactosidase (-gal)
vectors and were euthanized 7 days after injection. Robust
-gal staining indicating virtually complete transduction of
all muscle fibers in mice injected with AAV/CMV/-gal
compared with no detectable -gal staining in mice in-
jected with AAV/CMV/Luc (Fig 1, D).
EcSOD overexpression in nonischemic skeletal
muscles after AAV9/CMV/EcSOD intramuscular
injections. Left hind-limb skeletal muscles (TA and gas-
trocnemius) of BALB/c mice (n  10/group) were in-
jected with AAV9/CMV/EcSOD or AAV9/CMV/Luc
(5  1010 vg/muscle in 20 L). Mice were euthanized 14
days after injection and protein expression was assessed by
Western blot analysis. EcSOD expression was normalized
to GAPDH. EcSOD expression was 7.9-fold higher (P 	
.002) in the EcSOD group than in the Luc group (Fig 2).
EcSOD expression was also determined in nonischemic
C57BL/6 hind limbs, and an 8.2-fold increase in EcSOD
expression was observed in AAV9/CMV/EcSOD injected
limbs vs the control.
EcSOD protein expression in ischemic tissues is
increased in response to hind-limb ischemia. EcSOD
expression in the ischemic limbs of AAV9/CMV/EcSOD-
treated mice (n 10/group) was twofold higher (P	 .05)
than in the ischemic limbs of AAV9/CMV/Luc-treated
mice (Fig 3). EcSOD expression was normalized to
GAPDH.
EcSOD gene transfer improves hind-limb perfusion
recovery and reduces necrosis after hind-limb ischemia.
Hind-limb ischemia was surgically induced in left hind gimbs of EcSOD or Luc-treated BALB/c mice (n  10/
roup). Intramuscular injections of AAV/CMV/EcSOD
5  1010 vg/muscle, in 20 L) were given immediately
efore surgery. The entire surgical procedure was com-
leted in 20 to 25 minutes. Immediately after surgery on
ay 0, the perfusion ratio was 33.65%  1.7% for EcSOD
nd 32.80% 1.9% for Luc groups. At day 7, the perfusion
atio was 52.4% 3.5% in EcSOD-injected mice compared
ith 47.2%  2.0% in the Luc group. Thus, no significant
ifference in perfusion rate was found between EcSOD and
uc groups on day 0 or on day 7 after surgery. However,
he perfusion ratio at day 14 was 79.5% 1.7% in EcSOD-
njected mice compared with only 63.4% 1.1% in the Luc
roup (P 	 .01; Fig 4).
Fig 5 shows the number of mice with any necrosis and
he degree of necrosis postoperatively. For example, at 7
ays after injection, 4 of 10 mice in the EcSOD group
howed no visible signs of necrosis, whereas only 1 mouse
n the Luc group was similarly unafflicted. Furthermore, no
ice in the EcSOD group had grade 3 necrosis, whereas 3
ice in the Luc group had progressed to grade 3 by 7 days.
nonparametric Mann-WhitneyU test revealed significant
ifferences in necrosis between the two groups at all times
P 	 .05).
EcSOD modulates apoptosis and vascular density
ith no change in inflammation. To determine whether
he improved perfusion rate in the EcSOD group was
ssociated with a reduction in cellular apoptosis, apoptotic
ells were stained using the TUNEL assay (n 10/group)
he rate of TUNEL-positive apoptotic nuclei was 1.3% 
.4% in the EcSOD group and 4.15%  0.2% in the Luc
ig 4. Perfusion is improved in hind limbs treated with extracel-
ular superoxide dismutase (EcSOD). Mean perfusion ratio was
3.7% 1.7% for EcSOD and 32.8% 1.9% for control groups at
aseline on day 0 after hind-limb ischemia surgery and vector
njection. The EcSOD group demonstrated significantly better
erfusion recovery at day 14 than the control group (*P 	 .01).
AV, Adeno-associated virus; CMV, cytomegalovirus; Luc, lu-
iferase.roup (P 	 .001; Fig 6, A).
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Volume 54, Number 3 Saqib et al 815To determine if the improved perfusion in EcSOD
group involved angiogenesis, we sought to determine cap-
illary density at 14 days after hind-limb ischemia. Immuno-
fluorescence staining was performed for CD31, and fila-
mentous actin (F-actin) was detected on the same slides
with phalloidin. Vascular density (n  10/group) in the
EcSOD group (1.65  0.02 capillaries/muscle fiber) was
significantly higher than in the Luc group (0.78  0.17
capillaries/muscle fiber, P 	 .05; Fig 6, B).
To determine whether differences in the inflamma-
tory response were significantly involved in recovery
from hind-limb ischemia, we first looked for inflamma-
tory infiltrate in the nonischemic EcSOD-injected skele-
tal muscles. Mild inflammation was observed on hema-
toxylin and eosin staining in EcSOD and control groups.
Immunostaining for CD45-positive monocytes and
CD68-positive macrophages produced similar results
(Fig 7, online only). The ischemic EcSOD-injected and
control hind limbs at day 14 both showed grade 3 for
Fig 5. Necrosis scores were improved in mice treated with extra-
cellular superoxide dismutase EcSOD. A, Nine of 10 mice showed
some degree of necrosis in the adeno-associated virus (AAV)/
cytomegalovirus (CMV)/luciferase (Luc) control group 7 days
after vector injection, including 3 mice with grade 3 necrosis. B, In
the AAV/CMV/EcSOD-treated group, only six mice showed
some degree of necrosis, and none had grade 3 necrosis. *P	 .05.CD45-positive or CD 68-positive cells, but no difference cas noted between the control and EcSOD-injected
roups (Fig 8, online only).
EcSOD overexpression preserves muscle integrity
fter ischemic surgery. We investigated the tissue integ-
ity of the ischemic skeletal muscles in both groups by
taining for total actin and F-actin, a polymerized form of
ctin (n  10/group). Fluorescence immunostaining of
keletal muscles from both groups indicated very similar
atterns for total actin, but F-actin was significantly far
ore abundant and its distribution more homogeneous in
cSOD-treated muscles than in the control ischemic mus-
les (Fig 9).
EcSOD increases cGMP levels in ischemic muscle.
O exerts its effects by the stimulation of NO-sensitive
uanylyl cyclase. Activation of NO-sensitive guanylyl
yclase leads to enhanced production of the intracellular
essenger cGMP.22 We assessed levels of cGMP, the
roduct of NO-activated guanylate cyclase. Levels of
ig 6. A, Quantitative assessment of apoptosis expressed as the
ercentage of TUNEL-positive nuclei/total number of nuclei
n 10 per group). *P	 .001.B, Quantitative analysis of capillary
ensity expressed as the number of capillaries per muscle fiber (n
0 per group). *P	 .02. Error bars show the standard error of the
ean. AAV, Adeno-associated virus; CMV, cytomegalovirus;
cSOD, extracellular superoxide dismutase; Luc, luciferase;
UNEL, terminal deoxynucleotide transferase-mediated deoxyu-
idine triphosphate nick-end labeling.GMP were 4.6-fold higher (P 	 .01) in ischemic hind
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September 2011816 Saqib et allimbs from the EcSOD group (1.7  0.32 pmol/mg)
than in the Luc group (0.41  0.20 pmol/mg, Fig 10,
n  3/group), thus providing evidence that EcSOD
overexpression increases cGMP levels in ischemic
muscles.
DISCUSSION
Therapeutic angiogenesis remains an investigative ap-
proach for improving limb perfusion and clinical outcomes
in patients with established PAD. In this study, we used a
preclinical model of acute limb ischemia to evaluate the
effects of intramuscular injection(s) of an AAV9 vector
directing the expression of EcSOD. There were several
notable findings:
1. There was evidence of therapeutic angiogenesis, with an
increase in perfusion to ischemic hind limbs in the
EcSOD treatment group, even in a mouse strain known
to have a limited capacity to recover perfusion after
hind-limb ischemia.
2. Treatment with AAV9/CMV/EcSOD led to an in-
crease in capillary density and a reduction in apoptosis in
the ischemic muscles, all findings that are consistent
Fig 9. The preservation of filamentous actin (green)
extracellular superoxide dismutase (EcSOD) than in (A
(orange) are comparable in (D) EcSOD-treated and
cytomegalovirus; Luc, luciferase.is markedly improved in ischemic limbs treated with (C)
) control ischemic limbs, whereas the levels of total actin
(B) control groups. AAV, Adeno-associated virus; CMV,with an angiogenic response. cig 10. Levels of cyclic guanosine monophosphate (cGMP;
mol/mg tissue) in ischemic tissues from control and extracellular
uperoxide dismutase (EcSOD)-treated mice at 14 days after isch-
mia induction are significantly increased compared with the con-
rol group (n  3 per group). *P 	 .01. The error bars show the
tandard error of the mean. AAV, Adeno-associated virus; CMV,
ytomegalovirus; Luc, luciferase.
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Volume 54, Number 3 Saqib et al 8173. EcSOD treatment not only increased the levels of
EcSOD associated with the vasculature and interstitial
space but also resulted in detectable levels of EcSOD
within the muscle fibers that were efficiently transduced
by the AAV9 vector.
4. Ischemic skeletal muscles from the EcSOD treatment
group showed a 4.6-fold increase in cGMP levels than
those from the Luc group.
In this study, we demonstrated that tissue-restricted
overexpression of EcSOD promoted therapeutic angiogen-
esis in a preclinical model of acute limb ischemia using
BALB/c mice. The BALB/c strain was intentionally cho-
sen for these studies as a stringent test case because they
have been previously documented to have extremely poor
perfusion recovery after hind-limb ischemia.11 Recovery
from hind-limb ischemia in BALB/c mice is worse than
apolipoprotein E knockout mice, as documented by a study
conducted by Xie et al,20 where no evidence of necrosis was
seen in a similar model of hind-limb ischemia. A Medline
review of the past 17 years (1993 to 2010) revealed only
four instances in which therapeutic angiogenesis for acute
limb ischemia had been attempted in BALB/c mice.23-26
Several different strategies have been examined in stud-
ies of therapeutic angiogenesis to deliver therapeutic agents
in animal models. Sometimes the recombinant protein
itself was administered, but the utility of protein adminis-
tration is limited by the relatively short circulating half-life
and by the large quantity needed for therapeutic effect.27
Although our study was not designed to compare ade-
novirus with AAV, the degree of transduction achieved
with the intramuscular injection of AAV9 was substantially
higher than that achieved with naked DNA or adenovirus.
With naked DNA, only 2% of muscle fibers are transfected
after an intramuscular injection,28 whereas an intramuscu-
lar injection of adenovirus shows 1% to 2% overall transduc-
tion of muscle fibers, and 30% to 40% transduction is seen
in muscle fibers adjacent to the injection site 7 days after
injection.29,30
In the present study, we showed robust transduction of
skeletal muscles by AAV9, and gene expression was docu-
mented for at least 6 weeks. AAV2 has previously been
deployed in preclinical models of acute limb ischemia,31-33
but, to our knowledge, this is the first study to use the
highly efficient AAV serotype 9. Phase 1 clinical trials for
heart failure using other recently discovered serotypes of
AAV (AAV1/SERCA2a and AAV6/SERCA2a) are cur-
rently in progress.34,35
Previous studies have demonstrated that endogenous
EcSOD is important in postischemic neovascularization.9
Indeed, a recent study showed that EcSOD gene transfer
promotes blood flow recovery and improves capillary/
muscle fiber ratio in a hind-limb ischemia model that used
C57Bl/6 mice.36 However, this study used recombinant
adenovirus to deliver EcSOD, and the results may be
confounded by local inflammatory damage because wild-
type 5 adenovirus has long been known to provoke a
vigorous inflammatory response in skeletal muscle.37 Ourtudy shows that AAV9 did not provoke detectable inflam-
ation in skeletal muscle. Mild inflammation was detected
ith hematoxylin and eosin stain, but no difference was
ound between EcSOD-injected and control groups.
D45 staining for monocytes and CD68 staining for mac-
ophages also showed that it is unlikely that vector inflam-
ation accounted for the results.
The messenger molecule NO exerts its effects by the
timulation ofNO-sensitive guanylyl cyclase, which leads to
nhanced production of the intracellular messenger
GMP.22 Our study demonstrated cGMP was significantly
ore abundant in ischemic muscles that received EcSOD
reatment. It has been suggested that cGMP activates
ypoxia-inducing factor-1 transactivation activity at hy-
oxia, which is crucial in vascular endothelial growth factor
VEGF) synthesis by binding to the hormone responsive
lements in the VEGF promoter region and by subse-
uently upregulating VEGF transcription.38,39 A more
recise mechanism may become apparent by looking at
hese downstream mediators of cGMP. Endothelial NO
ynthase knockout (eNOS–/–) mice may also be used to
onfirm the involvement of the NO/cGMP pathway in
ostischemic angiogenesis in EcSOD-injected mice.
The present study demonstrates that EcSOD is impor-
ant in neovascularization in settings of hind-limb ischemia.
hese findings provide novel insight into use of exogenous
cSOD driven by the highly specific skeletal muscle vector
AV9 as a potential therapeutic agent for critical limb
schemia (PAD).
ONCLUSIONS
The present study demonstrated that AAV-mediated
ene transfer into mouse skeletal muscles results in efficient
nd stable gene expression. We also demonstrated that
AV-mediated EcSOD gene transfer stimulates angiogen-
sis and thereby improves blood flow and hence perfusion
ecovery in a murine hind-limb ischemia model.
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